

JUN 11 2007

Under the Pa
Substitute f

Approved for use through 09/30/2007. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

(Use as many sheets as necessary)

Sheet	1	of	3
-------	---	----	---

Complete if Known

Application Number	09/521,442
Filing Date	March 7, 2000
First Named Inventor	MENON, Gopinathan K.
Art Unit	1615
Examiner Name	VENKAT, Jyothsna A.
Attorney Docket Number	SC35U-US

U. S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

**Examiner
Signature**

/Bethany Barham/

Date
Considered

07/20/2007

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known	
		Application Number	09/521,442
		Filing Date	March 7, 2000
		First Named Inventor	MENON, Gopinathan K.
		Art Unit	1615
		Examiner Name	VENKAT, Jyothsna A.
Sheet 2	of 3	Attorney Docket Number	SC85U-US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/BB/		DRAELOS, D. & MARENUS, K.; Cellulite Biology and Purported Treatment; Dermatologic Surgery; Dec. 1997, p. 1177-1181, Vol. 23, Number 12.	
		ROSEN E. & SPIEGELMAN, B.; Adipocytes as regulators of energy balance and glucose homeostasis; Nature Publishing Group; 2006; p. 847-853.	
		LARSEN, T. et al; PPARgamma agonists in the treatment of type II diabetes; ; Intl. Journal of Obesity; Feb. 2003; p. 147-161, Vol. 27, No. 2.	
		MONTAGUE, C. et al; Depot-Related Gene Expression in Human Subcutaneous and Omental Adipocytes; Diabetes; Sept. 1998; p.1384-1391, Vol. 47.	
		AVRAM, A. et al.; Subcutaneous fate in normal and diseased states; J. Am. Aca. Dermatol.; Oct. 2005; p. 671-683; Vol. 53, No. 4.	
		Muller, Y. et al.; A Functional Variant in the Peroxisome Proliferator; Diabetes, July 2003; p. 1864-1871, Vol. 52.	
		HEXSEL, D. et al.; Botanical Extracts Used in the Treatment of Cellulite; Dermatol Surg.; July 2005; p 866-872, Vol. 31:7 Part 2.	
		SEMPLE, R. et al.; PPARγ and human metabolic disease; J. of Clinical Investigation; March 2006, p. 581-589, Vol. 116, No. 3.	
		AVRAM, M; Cellulite: a review of its physiology and treatment; J. Cosmet. Laser Ther.; 2004; p. 181-185, Vol. 6	
↓		GIUSTI, V. et al.; Expression of Peroxisome Proliferator; Diabetes; July 2003; p. 1673-1676, Vol. 52, No. 7.	

Examiner Signature	/Bethany Barham/	Date Considered	07/20/2007
--------------------	------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known	
		Application Number	09/521,442
		Filing Date	March 7, 2000
		First Named Inventor	MENON, Gopinathan K.
		Art Unit	1615
		Examiner Name	VENKAT, Jyothsna A.
Sheet 3	of 3	Attorney Docket Number	SC85U-US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/BB/		MORI, Y., et al.; Effect of Troglitazone on Body Fat Distribution in Type 2 Diabetic Patients; Diabetes Care, June 1999; p. 908-912, Vo. 22, No. 6.	
		VIDAL-PUIG, A. et al.; Peroxisome Proliferator-activated Receptor Gene Expression in Human Tissues; J. Clin. Invest.; May 1997, p. 2416-2422, Vol. 99, No. 10.	
		TSAI, Y. et al.; Hypertension and abnormal fat distribution but not insulin resistance in mice; J. of Clinical Investigation; July 2004, p. 240-249, Vo. 114, No. 2.	
		Rawlings, A.; Cellulite and its treatment; J. of Cosmetic Science; 2006; p. 175-190, Vol. 28.	
		BIRNBAUM, L.; Addition of Conjugated Linoleic Acid to a Herbal Anticellulite Pill; Advances in Natural Therapy; Sep/Oct. 2001, p. 225-229, Vol. 18, No. 5.	
		BERTIN, C. et al.; A double-blind evaluation of the activity of an anti-cellulite product; J. Cosmet. Sci; Jul/Aug 2001, p. 199-210, Vol. 52, No. 4.	
✓		RAO, J. et al., A two-center, double-blinded, randomized trial testing the tolerability and efficacy; J. of Cosm. Derm., 2005, p. 93-102, Vol. 4.	

Examiner Signature	/Bethany Barham/	Date Considered	07/20/2007
--------------------	------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.